Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.
In the adjuvant treatment of HR-positive/HER2-negative early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years.
What factors related to the patient or disease influences your decision to prescribe a CDK4/6 inhibitor in this setting?
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.